Overview

Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis

Status:
Completed
Trial end date:
2017-08-10
Target enrollment:
Participant gender:
Summary
This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells. They are used to treat anemia in patients with myelofibrosis.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Cancer Institute (NCI)
Treatments:
Danazol
Janus Kinase Inhibitors